Chemiluminescence (CL) is the emission of electromagnetic radiation as a result of a chemical reaction that produces light. Chemiluminescence immunoassay (CLIA) is a technique that combines chemiluminescence with immunochemical reactions. To label the antibody, CLIA employs chemical probes that can emit light as a result of a chemical reaction.
CLIA is used in a variety of fields, including life science, clinical diagnosis, environmental monitoring, food safety, and pharmaceutical analysis, due to its high sensitivity, good specificity, simple equipment, and wide linear range.
Global Chemiluminescence Immunoassay Market - Impact of the Coronavirus (COVID-19) Pandemic
Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 213 million cases and 4.48 million deaths due to coronavirus disease (COVID-19) were reported till August 25, 2021, across the globe.
Impact of COVID-19 on Demand and Supply of Chemiluminescence Immunoassay
The COVID-19 pandemic and lockdown in various countries across the globe has impacted the financial status of businesses across all sectors including private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. The COVID-19 pandemic has affected the economy of various regions across the globe in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Several countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation and distribution of healthcare products.
Understanding the specific antibody profile and immune response in COVID-19 patients, on the other hand, is critical for characterizing disease progression. Thus, impact of the coronavirus (COVID-19) pandemic is expected to drive the growth of the global chemiluminescence immunoassay market over the forecast period. For instance, according to the article published in nature communications, February 2021, a multiplex chemiluminescent immunoassay for serological profiling of COVID-19 was conducted in a healthy cohort of adults and children in Colorado, U.S. It was observed that COVID-19-positive symptomatic participants had significantly higher average IgG antibody titers against all antigens than COVID-19-positive asymptomatic participants. As a result, immune responses to SARS-CoV-2 may differ between asymptomatic and symptomatic COVID-19-positive participants. These findings may aid in differentiating individual immune responses in a wider population for tracking purposes.
The global chemiluminescence immunoassay market is estimated to be valued at US$ 6.01 Bn in 2021, and is expected to exhibit a CAGR of 8.0 % over the forecast period (2021-2028).
Figure 1: Global Chemiluminescence Immunoassay Market Share (%) Analysis, By Product Type, 2021
The increasing cases of diseases such as HIV (human immunodeficiency virus) requiring chemiluminescent immunoassay is expected to drive growth of the market over the forecast period.
The emerging prevalence of human immunodeficiency virus disease (HIV) is expected to bolster the growth of global chemiluminescence immunoassay market. For instance, according to the Centers for Disease Control and Prevention (CDC), in the U.S. and dependent areas, 36,801 people were diagnosed with HIV in 2019. At the end of 2019, an estimated 1,189,700 people in the U.S. had HIV, and 15,815 deaths among people with HIV were reported.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2020 | Market Size in 2021: | US$ 6.01 Billion |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2021 to 2028 |
| Forecast Period 2021 to 2028 CAGR: | 8.0 % | 2028 Value Projection: | US$ 10.1 Billion |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
DiaSorin S.p.A., Abbott Laboratories, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers, Beckman Coulter Inc., F. Hoffmann-La Roche AG, Inova Diagnostics, Inc., Maccura Biotechnology Co., Ltd., Tosoh Corporation, and Ortho Clinical Diagnostic. |
||
| Growth Drivers: |
|
||
Research and Development Activities
Increase in the research and development activities related to chemiluminescent immunoassay is expected to provide lucrative growth of global chemiluminescence immunoassay market. For instance, according to article published in Frontiers in Microbiology, January 2021, the researchers at Yokohama City University Hospital and Kanagawa Cardiovascular & Respiratory Center with the support of Japan Agency for Medical Research and Development (AMED) developed an automated Chemiluminescence Assay System. The assay is designed to quantitatively measure multiple anti-SARS-CoV-2 antibodies.
Global Chemiluminescence Immunoassay Market – Regional Analysis
On the basis of region, the global chemiluminescence immunoassay market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to hold dominant position in the global chemiluminescence immunoassay market over the forecast period, owing to the acquisitions by market players. For instance, on May 17, 2021, PerkinElmer, Inc., a U.S. based based focused on developing unique solutions to serve diagnostic and life science markets, announced the acquisition of Immunodiagnostic Systems Holdings PLC, manufacturer of in-vitro diagnostic tests. Through this acquisition, PerkinElmer plans to develop its Diagnostics enterprise and specially its immunodiagnostics segment. Moreover, the deal will permit PerkinElmer to combine its expertise and testing abilities with IDS’s chemiluminescence products in endocrinology, autoimmunity, and infectious illnesses to serve clients across the world.
Moreover, due to new product launches and approvals by market players, Europe is expected to witness a significant growth in global chemiluminescence immunoassay market over the forecast period. For instance, on July 13, 2021, Sysmex Europe GmbH, a company based near Hamburg, Germany and a subsidiary of the Sysmex Corporation, announced the launch of new hemostasis products in specific EMEA countries: the automated blood coagulation analyzers CN-3500 and CN-6500, aimed at medium- and large-scale hospitals, commercial labs, and other facilities. Sysmex's new instruments include a measuring unit that employs the chemiluminescence enzyme immunoassay methodology.
Figure 2: Global Chemiluminescence Immunoassay Market Value (US$ Bn), by Region, 2021
Global Chemiluminescence Immunoassay Market – Competitive Landscape
Major players operating in the global chemiluminescence immunoassay market include DiaSorin S.p.A., Abbott Laboratories, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers, Beckman Coulter Inc., F. Hoffmann-La Roche AG, Inova Diagnostics, Inc., Maccura Biotechnology Co., Ltd., Tosoh Corporation, and Ortho Clinical Diagnostic.
Chemiluminescent immunoassay (CLIA) is a biochemical technique used in immunology that is a variation of the standard enzyme immunoassay (EIA). They can also be used as diagnostic tools in medicine, as well as in a variety of other industries such as for food safety and pharmaceutical analysis, environmental monitoring, and many more.
There are two type of chemiluminescence immunoassay methods:
Market Dynamics
Market players are focused on supplying products to hospitals and government organizations, this could contribute to the growth of the global chemiluminescence immunoassay market over the forecast period. For instance, on June 22, 2020, Abbott Laboratories, located in Mumbai, India, began to distribute its laboratory-based serology blood test for the detection of the antibody IgG (Immunoglobulin G), which determines whether a person has been infected with the novel coronavirus (COVID-19). Abbott has the capacity to supply millions of tests to India and has delivered antibody tests to leading government and private hospitals and labs in Maharashtra, Delhi, West Bengal, Uttar Pradesh, Jammu & Kashmir, and Gujarat. The SARS-CoV-2 IgG test from Abbott can be used for highly reliable, large-scale antibody testing, as recommended by the ICMR (Indian Council of Medical Research) for the use of IgG CLIA (Chemiluminescence immunoassay) tests.
Market players focused on product launches is expected to propel the growth of the global chemiluminescence immunoassay market. For instance, on July 25, 2019, STRATEC SE, a global company that develops and manufactures analyzer systems and automation systems for in-vitro diagnostics, has taken another step toward diversifying its product portfolio by introducing stand-alone modules and a new chemiluminescence immunoassay KleeYa. The KleeYa analyzer is an open platform system that can be used by a variety of providers.
Market players and government authorities are involved in expanding their global presence by adopting strategies such as acquisitions and collaborations, is expected to drive the growth of the global chemiluminescence immunoassay market. For instance, on November 16, 2020, Biomedical Advanced Research and Development Authority (BARDA), U.S. expanded its existing partnership with DiaSorin Inc. in the development of COVID-19 immunoassays. DiaSorin plans to develop and sell its new fully automated chemiluminescence immunoassay in the U.S. and around the world and obtain regulatory approval for semi-quantitative detection of SARS CoV2 virus IgG antibodies in human serum and plasma. The test is designed to help determine the patient's exposure and immune status to the SARSCoV2 virus and COVID-19.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients